KC706 ( DrugBank: KC706 )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
35	Pemphigus	1
46	Malignant rheumatoid arthritis	1

35. Pemphigus

---

Clinical trials : 98 /  Drugs : 126 - (DrugBank : 41) / Drug target genes : 23 - Drug target pathways : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00606749 (ClinicalTrials.gov)	November 2007	22/1/2008	Use of KC706 for the Treatment of Pemphigus Vulgaris	A Phase 2 Open-Label Uncontrolled Pilot Study of KC706 in Patients With Stable, Active Pemphigus Vulgaris	Pemphigus Vulgaris	Drug: KC706	Kemia, Inc	NULL	Completed	18 Years	N/A	Both	20	Phase 2	United States

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-002645-37-HU (EUCTR)	25/08/2006	13/06/2006	A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate	A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate	Active rheumatoid arthritis (RA), patients taking stable doses of methotrexate MedDRA version: 8.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: KC706 Product Code: KR002524	Kémia, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2	Hungary